不同的腹腔热灌注化疗药物治疗晚期卵巢癌临床分析  

Clinical analysis of different intraperitoneal hyperthermic chemotherapy drugs in the treatment of advanced ovarian cancer

作　　者：赵月明[1] 黄冬梅[1] 孙欣欣[1] 

机构地区：[1]郑州大学第二附属医院妇产科,河南省郑州市450014

出　　处：《实用医学杂志》2017年第8期1320-1323,共4页The Journal of Practical Medicine

基　　金：河南省科学技术发展计划项目(编号:112102310505)

摘　　要：目的:研究两组不同的腹腔热灌注化疗药物治疗晚期卵巢癌的近期疗效及不良反应。方法:将2013年7月至2015年11月76例晚期卵巢癌患者分为两组,单药组36例(肿瘤细胞减灭术后行腹腔热灌注5-氟尿嘧啶化疗联合静脉化疗)和联合用药组40例(肿瘤细胞减灭术后行腹腔热灌注5-氟尿嘧啶+卡铂化疗联合静脉化疗)。分析两组近期疗效、术后临床指标及静脉化疗后毒副反应。结果:单药组与联合用药组治疗后CA125有效率分别是86.11%,95.00%,差异有统计学意义(P<0.05),腹水缓解率分别是97.22%,97.50%,差异无统计学意义(P>0.05)。两组术后腹胀时间对比差异有统计学意义(P<0.05)。两组患者药物不良反应比较:骨髓抑制、肝功损伤分布、胃肠道反应方面差异有统计学意义,两组患者肾功损伤分布、心血管系统损伤等方面差异无统计学意义。结论:术后腹腔热灌注化疗是晚期卵巢癌患者的有效辅助化疗手段,联合用药近期疗效明显,不良反应可耐受,临床可根据患者的具体情况选择。Objective To explore short term curative effects and adverse reactions of two different kinds of intraperitoneal hyperthermic chemotherapy （IPHC） drugs in the treatment of advanced ovarian cancer after cytoreductive surgery. Methods 76 patients with advanced ovarian cancer in the Second Affiliated Hospital of Zhengzhou University from July 2013 to November 2015 were divided into two groups： single-drugs group of 36 patients （IPHC with 5-fluorouracil after eytoreductive surgery combined with intravenous chemotherapy）, combined treatment group of 40 patients（IPHC with 5-fluorouraeil and carboplatin after cytoreductive surgery combined with intravenous chemotherapy）. Short term curative effects, postoperative clinical indicators and adverse reactions of chemotherapy in two groups were compared and analyzed. Results The CA125 effective rates in single-drugs and combined treatment group were 86.11% and 95%, and the difference showed statistically significant differences （P 〉 0.05）. The ascites remission rates in single-drugs and combined treatment group were 97.22% and 97.5%, and the difference between two groups showed no statistically significant differences （P 〉 0.05）. Adverse drug reactions showed statistical difference in distribution of the bone marrow, liver damage and gastrointestinal toxicity. No statistical difference were found between the two groups in terms of distribution of renal damage and cardiovascular system damage. Conclusion IPHC after cytoreductive surgery in the treatment of advanced ovarian cancer is an effective means as adjuvant chemotherapy. The short-term curative effect of combined treatment group is obvious and adverse reactions can be tolerated. IPHC can be applied according to the patient＇s specific clinical situation.

关 键 词：腹腔热灌注化疗 晚期卵巢癌 5-氟尿嘧啶 卡铂 

分 类 号：R737.31[医药卫生—肿瘤]